Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.

Citation data:

Drug metabolism and disposition: the biological fate of chemicals, ISSN: 1521-009X, Vol: 45, Issue: 3, Page: 260-268

Publication Year:
2017
Usage 12
Abstract Views 12
Captures 21
Readers 20
Exports-Saves 1
Mentions 2
News Mentions 2
Social Media 3
Shares, Likes & Comments 2
Tweets 1
Citations 4
Citation Indexes 4
Repository URL:
https://repository.hkbu.edu.hk/hkbu_staff_publication/6357
PMID:
28053220
DOI:
10.1124/dmd.116.073890
Author(s):
Cheong, Eleanor Jing Yi; Goh, Janice Jia Ni; Hong, Yanjun; Venkatesan, Gopalakrishnan; Liu, Yuanjie; Chiu, Gigi Ngar Chee; Kojodjojo, Pipin; Chan, Eric Chun Yong
Publisher(s):
American Society for Pharmacology & Experimental Therapeutics (ASPET); American Society for Pharmacology and Experimental Therapeutics (ASPET)
Tags:
Pharmacology, Toxicology and Pharmaceutics; Rivaroxaban; Amiodarone; Dronedarone; CYP3A4; CYP2J2; P-glycoprotein; Static modeling
Most Recent Tweet View All Tweets
Most Recent News Mention
article description
Rivaroxaban, a direct Factor Xa inhibitor, is indicated for stroke prevention in nonvalvular atrial fibrillation (AF). Studies have revealed that the clearance of rivaroxaban is largely attributed to CYP3A4, CYP2J2 metabolism, and P-glycoprotein (P-gp) efflux pathways. Amiodarone and dronedarone are antiarrhythmic agents employed in AF management. Amiodarone, dronedarone, and their major metabolites, N-desethylamiodarone (NDEA) and N-desbutyldronedarone (NDBD), demonstrate inhibitory effects on CYP3A4 and CYP2J2 with U.S. Food and Drug Administration-recommended probe substrates. In addition, both amiodarone and dronedarone are known P-gp inhibitors. Hence, the concomitant administration of these antiarrhythmic agents has the potential to augment the systemic exposure of rivaroxaban through simultaneous impairment of its clearance pathways. Currently, however, clinical data on the extent of these postulated drug-drug interactions are lacking. In this study, in vitro inhibition assays using rivaroxaban as the probe substrate demonstrated that both dronedarone and NDBD produced reversible inhibition as well as irreversible mechanism-based inactivation of CYP3A4- and CYP2J2-mediated metabolism of rivaroxaban. However, amiodarone and NDEA were observed to cause reversible inhibition as well as mechanism-based inactivation of CYP3A4 but not CYP2J2. In addition, amiodarone, NDEA, and dronedarone, but not NDBD, were determined to inhibit P-gp-mediated rivaroxaban transport. The in vitro inhibition parameters were fitted into a mechanistic static model, which predicted a 37% and 31% increase in rivaroxaban exposure due to the inhibition of hepatic and gut metabolism by amiodarone and dronedarone, respectively. A separate model quantifying the inhibition of P-gp-mediated efflux by amiodarone or dronedarone projected a 9% increase in rivaroxaban exposure.